AbbVie

1591 articles about AbbVie

• AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

  5/6/2023

  AbbVie announced it will present 29 abstracts during the 2023 Digestive Disease Week Annual Meeting, May 6-9, 2023, being held in Chicago and virtually.

• AbbVie to Present at the Bank of America Securities Healthcare Conference

  5/2/2023

  AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023.

• 

  The Top 12 Biopharma Companies Hiring Now

  5/1/2023

  In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.
• 

  Humira Sales Down 25% as AbbVie Cuts Two Programs 

  4/28/2023

  As Humira global revenues fall 25%, AbbVie looks to Rinvoq and Skyrizi to fill in the gap. The company also announced it is cutting cystic fibrosis and Crohn’s disease candidates.

• AbbVie Reports First-Quarter 2023 Financial Results

  4/27/2023

  AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2023.

• 

  AbbVie's Migraine Drug Scores Another Phase III Win

  4/21/2023

  AbbVie shared more positive results for its migraine prevention drug, Qulipta, just three days after FDA approval to expand its label.

• AbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 AAN Annual Meeting

  4/21/2023

  AbbVie announced positive data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of oral preventive medications.

• 

  AbbVie Wins FDA Approval for New Migraine Indication

  4/19/2023

  Qulipta’s label expansion makes it the first oral CGRP receptor antagonist approved for episodic and chronic migraine.

• U.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine

  4/18/2023

  AbbVie announced that the U.S. Food and Drug Administration has approved expanding the indication of QULIPTA® for the preventive treatment of migraine in adults.

• 

  10 Biopharma Companies Hiring AI/ML Talent Now

  4/17/2023

  To help with your job search, here are 10 biopharma companies hiring for Artificial Intelligence and Machine Learning (AI/ML) roles now.
• 

  Reformulated: New Takes on Parkinson’s Disease Treatments

  4/17/2023

  Between new formulations of traditional drugs nearing the market and completely novel approaches in mid-stage trials, 2023 is poised to be a pivotal year in Parkinson’s disease treatment.

• AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease

  4/17/2023

  AbbVie announced the European Commission approved RINVOQ® as the first oral Janus Kinase inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

• 

  AbbVie, J&J Pull Two Accelerated Approvals for Imbruvica

  4/10/2023

  AbbVie and Johnson & Johnson will withdraw the accelerated approvals for Imbruvica in mantle cell lymphoma and marginal zone lymphoma, the companies announced Thursday.
• 

  FDA Action Alert: Alvotech, Otsuka and More

  4/10/2023

  The FDA is set to decide on a Humira biosimilar and hold an Adcomm meeting for an Alzheimer’s agitation treatment. Also on its calendar for April are decision dates for two vaccine hopefuls.

• AbbVie to Host First-Quarter 2023 Earnings Conference Call

  4/4/2023

  AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens.

• Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023

  3/29/2023

  Allergan Aesthetics, an AbbVie company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world.

• 

  AbbVie Clinches Back-to-Back Clinical Wins in Ulcerative Colitis, Lupus

  3/24/2023

  In a double data drop Thursday, AbbVie touted two clinical trial wins, for Skyrizi in ulcerative colitis and Rinvoq in systemic lupus erythematosus.

• Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

  3/23/2023

  AbbVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI®,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis.

• AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

  3/23/2023

  AbbVie (NYSE: ABBV) today announced topline results from a Phase 2 study of upadacitinib (RINVOQ®, 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE).

• AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application

  3/22/2023

  AbbVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.